Natera (NASDAQ:NTRA – Get Rating) had its price objective upped by BTIG Research to $95.00 in a report released on Monday, Stock Target Advisor reports.
Several other research firms also recently issued reports on NTRA. Robert W. Baird dropped their target price on Natera from $100.00 to $71.00 in a research report on Friday, May 6th. The Goldman Sachs Group dropped their target price on Natera from $90.00 to $80.00 and set a buy rating on the stock in a research report on Tuesday, April 19th. Cowen lowered their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Cowen lowered their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Finally, Stephens initiated coverage on Natera in a research report on Monday, April 25th. They issued an overweight rating and a $54.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $92.73.
Get
Natera alerts:
Natera Price Performance
Natera stock opened at $56.68 on Monday. Natera has a 12 month low of $26.10 and a 12 month high of $129.09. The company has a current ratio of 3.58, a quick ratio of 3.46 and a debt-to-equity ratio of 0.63. The business's 50 day simple moving average is $42.21 and its 200 day simple moving average is $44.79. The company has a market cap of $5.50 billion, a price-to-earnings ratio of -9.35 and a beta of 1.33.
Natera (NASDAQ:NTRA – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The medical research company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.47) by ($0.03). The firm had revenue of $198.20 million during the quarter, compared to analysts' expectations of $193.67 million. Natera had a negative net
margin of 79.57% and a negative return on equity of 95.97%. Natera's revenue for the quarter was up 39.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) EPS. Sell-side analysts forecast that Natera will post -5.73 EPS for the current year.
Insider Activity at Natera
In related news, COO Robert Alan Schueren sold 572 shares of the stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $46.26, for a total value of $26,460.72. Following the transaction, the chief operating officer now owns 572 shares of the company's stock, valued at $26,460.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Steven Leonard Chapman sold 886 shares of the firm's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $46.26, for a total transaction of $40,986.36. Following the transaction, the chief executive officer now directly owns 69,805 shares of the company's stock, valued at $3,229,179.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Robert Alan Schueren sold 572 shares of the firm's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $46.26, for a total value of $26,460.72. Following the transaction, the chief operating officer now directly owns 572 shares in the company, valued at $26,460.72. The disclosure for this sale can be found here. Insiders have sold a total of 13,966 shares of company stock valued at $550,755 over the last 90 days. 10.27% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp grew its stake in shares of Natera by 15.2% during the first quarter. Fifth Third Bancorp now owns 6,090 shares of the medical research company's stock valued at $248,000 after buying an additional 805 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Natera by 2.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 678,499 shares of the medical research company's stock worth $63,365,000 after purchasing an additional 17,976 shares during the period. Rehmann Capital Advisory Group purchased a new stake in shares of Natera during the fourth quarter worth about $606,000. Dimensional Fund Advisors LP boosted its holdings in shares of Natera by 11.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 126,507 shares of the medical research company's stock worth $11,814,000 after purchasing an additional 12,866 shares during the period. Finally, CWM LLC boosted its holdings in shares of Natera by 1,041.0% during the first quarter. CWM LLC now owns 696 shares of the medical research company's stock worth $28,000 after purchasing an additional 635 shares during the period. 96.24% of the stock is owned by institutional investors.
Natera Company Profile
(Get Rating)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Skyworks Solutions Is Worth A Look At These Prices
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
